We increasingly understand the role of immune activation and (neuro)inflammation in the background of suicidal behaviour, and insight to the processes involved may pinpoint much needed novel target for pharmacological prevention and management of suicide risk. besides a wide range of studies focusing on inflammatory mediators and peripheric proinflammatory cytokines, less attention is yet paid to purinergic signalling. Recently, purinergic receptor P2X7 (P2X7R), an ATP-sensitive ligand-gated nonselective cation channel, expressed in the brain primarily by microglia has been implicated in the background of depression and suggested as a potential target of novel antidepressive drugs. Activation of P2X7R by a marked increase in extracellular ATP leads to the NLRP3 inflammasome com-plex-mediated release of proinflammatory cytokines and neurotransmitters to the extracellular space. In spite of studies underlining its potential role in depression, it was less investigated in connection with suicide. The presentation will outline novel results concerning an association between the P2RX7 gene and current suicidal risk markers, in part in interaction with early childhood traumas, while overviewing how we can exploit neuroinflammation in the treatment of suicide risk.